H B
@ .
1
D P ,B
H ,75F ,B ,MA02120, A
+B M N 2016
1
1
1
1
D (DOAC )
P D
IN A , ( E),
-
1 . E
500,000 .A -
, -
24 .A
E. O K
( KA), ,
E .
,
, , -
, , -
57 .
, (DOAC ), -
, , ,
E.D -
. -
, ,
.DOAC KA,
, , -
able pharmacokinetic profles, decreased coagulation moni-
, 8 10 . M
DOAC
E
11 15 .A ,
A ED -
DOAC
( E)
has been confned to parenteral agents and oral vitamin K
; ,
(DOAC ),
.
E
. A
E -
. O 105 , 45
(43%) 60 (57%)
DOAC.
most common DOACs initiated. There were signifcantly
CC
<60 / DOAC
(77.8% . 15%; P < 0.05). There were signifcantly less
-
DOAC (15.6% . 55%;
P <0.05). P DOAC
( 2.5 I 0 4 . 6
I 5 7 , <0.05).P DOAC
( 3 I 24 . 8
I 6 10 , <0.05). DOAC
new onset VTE. Renal and liver function may infuence
. DOAC
.
1 3
J Thromb Thrombolysis (2017) 43:74–78
DOI 10.1007/s11239-016-1417-5
Published online: 3 September 2016